LABIANA HEALTH S.A.EO-10 - Asset Resilience Ratio
LABIANA HEALTH S.A.EO-10 (8RK) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does LABIANA HEALTH S.A.EO-10 carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how LABIANA HEALTH S.A.EO-10's Asset Resilience Ratio has changed over time. See net assets of LABIANA HEALTH S.A.EO-10 for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down LABIANA HEALTH S.A.EO-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 8RK market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €800.25 | 0.0% |
| Total Liquid Assets | €800.25 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LABIANA HEALTH S.A.EO-10 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LABIANA HEALTH S.A.EO-10 Industry Peers by Asset Resilience Ratio
Compare LABIANA HEALTH S.A.EO-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for LABIANA HEALTH S.A.EO-10 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for LABIANA HEALTH S.A.EO-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €800.25 ≈ $935.58 |
€52.00 Million ≈ $60.80 Million |
-0.02pp |
| 2023-12-31 | 0.02% | €13.94K ≈ $16.30K |
€59.12 Million ≈ $69.12 Million |
+0.01pp |
| 2022-12-31 | 0.01% | €9.10K ≈ $10.64K |
€60.78 Million ≈ $71.06 Million |
0.00pp |
| 2021-12-31 | 0.02% | €11.45K ≈ $13.38K |
€68.37 Million ≈ $79.93 Million |
-- |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more